Drug intelligence / Profile preview

frovocimab

Development stage: Phase 2
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

Frovocimab (LY3015014) is a humanized IgG4 monoclonal antibody developed by Eli Lilly for the treatment of hypercholesterolemia. It acts as a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, binding to and neutralizing PCSK9. By inhibiting PCSK9, frovocimab prevents the degradation of low-density lipoprotein receptors (LDLR), thereby increasing LDLR levels on hepatocytes and enhancing clearance of LDL cholesterol from the bloodstream. Frovocimab has been investigated in phase II clinical trials for hypercholesterolemia[1][2][7].

Other names: frovocimabLY3015014LY-3015014LY 3015014

Targets

PCSK9 (Proprotein convertase subtilisin/kexin type 9)

Beyond the preview

Go deeper on frovocimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on frovocimab.

Explore the full profile